Introduction
============

COPD is a common disease that imposes a high burden on health care resources worldwide.[@b1-copd-13-1913],[@b2-copd-13-1913] The prevalence of COPD varied from 11.4% to 26.1%.[@b1-copd-13-1913] In Hong Kong (HK), the prevalence rates of COPD in the elderly population aged ≥60 years were 25.9% and 12.4% based on two different definitions with different spirometric criteria (postbronchodilator FEV~1~/FVC \<70% or lower limit of normal range).[@b3-copd-13-1913] In HK, the crude mortality rate of COPD was 29.1/100,000, while the crude hospitalization rate was 193/100,000 in 2005.[@b4-copd-13-1913] COPD ranked second (to respiratory infections) as a respiratory cause for hospitalization and inpatient bed-days. In elderly subjects aged ≥75 years, the hospitalization rate for COPD was as high as 2,225/100,000.[@b4-copd-13-1913] The economic burden of COPD on the society is enormous.[@b5-copd-13-1913],[@b6-copd-13-1913]

Previous studies gave information on the overall morbidity, mortality,[@b4-copd-13-1913] and the prevalence of COPD in HK.[@b3-copd-13-1913],[@b7-copd-13-1913] COPD patients in HK were undertreated compared with those in other countries. For example, the use of inhaled long-acting anti-muscarinic agent (LAMA) in HK (3.9%) was much lower than that in the other countries.[@b8-copd-13-1913] No large-scale study has looked into other details of COPD patients in HK.[@b9-copd-13-1913] There was no information on the severity of illness of a large COPD cohort requiring hospital admission in HK and how much resources they require in terms of length of hospital stay, medications, noninvasive mechanical ventilation (NIV), and invasive mechanical ventilation (IMV). There was also little information on the outcome of these patients over time.

Detailed studies of a large population of COPD patients involve immense resources. Demographic data of the COPD patients, their severity of disease, comorbidities, use of health care resources, and mortality would be invaluable for health care planning to manage the disease in the public sector. In HK, almost 95% of the population relied on the Hospital Authority (HA) for hospital medical service. All patient admissions under the HA were computerized and recorded in the clinical management system (CMS), but additional diagnosis and procedure coding had to be performed by the attending physician. It is possible to perform data retrieval with the HA Clinical Data Analysis and Reporting System (CDARS) software program.[@b10-copd-13-1913],[@b11-copd-13-1913] A pilot study was carried out in one center in 2010.[@b10-copd-13-1913] Patients with the principal discharge diagnosis of COPD were identified, and a computerized report of their demographic data and the use of medical resources was generated using CDARS. Some of the data still required manual capture and case record review. We have extended the study to include a large COPD cohort based entirely on the CDARS and without the need of individual patient record review. No additional research assistant had been employed for the purpose of this study.

Patients and methods
====================

Study design and patient recruitment
------------------------------------

This was a multicentered retrospective study of COPD patients discharged from the medical departments of 13 public regional hospitals and 3 chest hospitals of the HA in HK, during the period from 1 January to 31 December 2012. A list of participating hospitals is provided in the Supplementary material. This list included all except one public acute regional hospital (with 24-hour acute emergency service) and all except one chest hospital in HK from 2012 to 2014. Data retrieval was performed with the HA CDARS.[@b10-copd-13-1913],[@b11-copd-13-1913] All patients with the principal diagnosis of COPD (International Classification of Diseases \[ICD\] codes 491, 491.2, 491.21, 492, 492.8, and 496) on discharge in 2012 were included. The inclusion criteria were as follows: 1) aged \>40 years; 2) principal discharge diagnosis of COPD (with ICD codes as described earlier); and 3) discharge from the medical departments of the respective hospitals. The exclusion criteria included the following: 1) aged ≤40 years and 2) patients discharged from specialties other than Department of Medicine.

Case record review and data entry of individual patients were not required. The group data that were retrieved by CDARS included the following: 1) demographic data; 2) total number of admissions for each subject between 1 January and 31 December 2012; 3) total length of hospital stay in 2012; 4) number of attendances at accident and emergency departments (A&E) and at specialist outpatient clinics (SOPCs); 5) coding of lung function tests and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification (ever performed, if available); 6) treatment modalities including acute NIV (ICD code 93.9) and IMV (ICD code 96.70, 96.71, and 96.72); 7) medications used including inhaled corticosteroids (ICSs), long-acting beta-agonists (LABA), LAMA, or their combinations; 8) comorbidities (including hypertension, ischemic heart disease, diabetes mellitus, chronic effects of tuberculosis \[old TB\], bronchiectasis, congestive heart failure, and asthma) that were coded in previous hospital admissions; 9) mortality of those recruited patients from 1 January, 2012, to 31 December, 2014; and 10) the cause of death estimated from the principal diagnosis for the episode of hospital discharge which ended up in death.

The data that require coding by physicians included the principal and secondary diagnosis, procedure coding, and lung function coding. Coding for lung function was not mandatory for the diagnosis coding of COPD. For patients with spirometry data available, the GOLD criteria of post-bronchodilator FEV~1~/FVC ratio \<70% and FEV~1~% predicted were used for the diagnosis and staging of COPD.[@b12-copd-13-1913]

The study was approved by the Clinical Research Ethics Committees of all the participating hospitals. As this was a retrospective study with no active intervention, patient consent was not required by our Clinical Research Ethics Committees for research projects that involve only review of medical information. Furthermore, individual case record was not performed for this study. Only clinical data without patients' personal information were sent to the coinvestigators for analysis.

Statistical analysis
--------------------

The CDARS provided simple statistical analysis with mean and SD of the whole group and subgroups defined by different parameters. Additional statistical evaluations, eg, comparisons between subgroups, were performed using the SPSS Version 22 software package (IBM Corporation, Armonk, NY, USA). Data were expressed as mean ± SD. Comparisons between two groups were made by using the *χ*^2^ test for categorical data, and unpaired student *t*-tests were used for continuous data where appropriate. Different stages of GOLD classification were compared by one-way analysis of variance and the Games-Howell post hoc tests. To test for any trend across stages of GOLD classification, the *χ*^2^ tests for linear trend were used for categorical data. All reported *p*-values were two-sided. A *p*-value \<0.05 is considered statistically significant.

Results
=======

Patient characteristics
-----------------------

There were a total of 9,776 patients with the principal diagnosis of COPD during the study period with a total of 19,795 hospitalization episodes. [Table 1](#t1-copd-13-1913){ref-type="table"} shows the demographic characteristics of the subjects. The subjects were mostly elderly with a mean age of 78.0±9.4 years, and 82.6% were men; 1,918 subjects (19.6%) had lung function tests ever performed that was coded in the admissions in 2012, and 85 (4.4%), 488 (25.5 %), 808 (42.1%), and 537 (28.0%) of the 1,918 subjects with lung function coding had GOLD 1, 2, 3, and 4 classes, respectively. The lung function test might have been performed in 2012 or earlier. The version of CDARS in 2012 was not able to ascertain the year of lung function performed. Patients with GOLD 3 and 4 COPD were 3 years younger than those with GOLD 1 and 2 COPD (74.9 vs 77.8 years, *p*\<0.001). The mean age of female patients (F) was higher than that of male patients (M) for the whole group, all GOLD classes and those without lung function coding ([Table 1](#t1-copd-13-1913){ref-type="table"}).

Use of health care resources
----------------------------

[Table 2](#t2-copd-13-1913){ref-type="table"} shows the use of health care resources of the subjects including attendance at A&E and SOPC, number of hospital admissions, and use of NIV and IMV. The subjects had an average of 3.8 emergency department visits and an average of 2.0 hospitalizations during the year 2012. Increasing GOLD stages were associated with more hospital admissions, longer length of hospital stay, SOPC attendances, higher percentage of NIV use during hospitalizations, and higher mortality (in the same year and after 2 years). Overall, 2,278 of 9,776 (23.3%) subjects required NIV during admission, whereas 309 of 537 (57.5%) patients with GOLD 4 disease had been treated with NIV. The use of IMV was low among all GOLD classes (overall 1.4%). Compared with patients without lung function coding (n=7,858), patients with lung function coding (n=1,918) had more attendance at A&E and SOPC, more hospitalizations, longer hospital stay (17.9 vs 11.0 days, *p*\<0.001), and more requirement of NIV (39.8% vs 19.3%, *p*\<0.001).

Pharmacotherapy and GOLD class
------------------------------

[Table 3](#t3-copd-13-1913){ref-type="table"} shows the pharmacotherapy for COPD among recruited subjects. Overall, 9.9% of subjects were on LABA alone, 1% on LAMA alone, and 33.6% on ICS alone; 16.4% on LABA and LAMA combination, 10.1% on ICS and LABA, and 3.4% on ICS with LAMA; and 10.5% on triple therapy with ICS, LABA, and LAMA. Among subjects with and without lung function coding, 79.6% and 44.3% of the subjects were on at least one long-acting bronchodilator (LAMA and/or LABA), respectively. Patients without lung function coding were more likely to be on ICS alone (37.8% vs 16.3%, *p*\<0.001). With increasing severity of GOLD class, more subjects were on combination of LABA and LAMA with or without ICS.

Comorbidities and GOLD class
----------------------------

[Table 4](#t4-copd-13-1913){ref-type="table"} shows the comorbidities of COPD subjects. In total, 5,923 subjects (60.6%) had at least one of the comorbidities listed (hypertension, ischemic heart disease, diabetes mellitus, old TB, bronchiectasis, congestive heart failure, and asthma). Hypertension and diabetes mellitus were more common in patients with GOLD 1 and 2 (41.5% and 16.6%, respectively) than in patients with GOLD 3 and 4 diseases (35.0% and 12.5%, respectively). [Figure 1](#f1-copd-13-1913){ref-type="fig"} shows the comorbidities of the subjects in relation to the GOLD class of lung function. Patients with lower GOLD classes were more likely to have hypertension (*p*=0.001), while patients with higher GOLD classes were more likely to have chronic effect of TB (*p*=0.048). There were no significant differences for ischemic heart disease, bronchiectasis, congestive heart failure, or asthma with different GOLD classes.

Mortality and causes of death
-----------------------------

The causes of death could only be retrieved by CDARS for patients who died in the HA hospitals. For patients who died outside the HA hospitals (including those who were certified dead at A&E), the identity of the patients could be retrieved from the death registry, but the cause of death could not be ascertained by the CDARS. For patients who died in the HA hospitals, 503 of 9,776 (5.1%) patients died in 2012 due to COPD (5.1%), while the total all-cause mortality was 1,585 of 9,776 (16.2%). Review of the cumulative all cause-mortality in the HA hospitals showed that 2,877 (29.4%) patients had died by the end of 2013 and 3,867 (39.6%) patients had died by the end of 2014 ([Table 5](#t5-copd-13-1913){ref-type="table"}). The top common causes of death were pneumonia (32.3%), COPD (30.1%), lung cancer (6.3%), other malignancies (4.0%), and respiratory failure (3.9%). Death from ischemic heart disease (2.7%), heart failure (1.8%), and cerebrovascular accident (1.0%) accounted for 5.5% of deaths due to cardiovascular causes.

As on 31 December, 2014, 3,876 of 9,776 (39.6%) and 560 of 9,776 (5.7%) of patients had died in and outside the HA hospitals, respectively ([Table 5](#t5-copd-13-1913){ref-type="table"}). Of the 560 cases with death outside the HA hospitals, 397 (70.9%) patients were certified dead at A&E department. The total mortality rate was 4,427/9,776 (45.3%) as in December 2014. The mortality rate of patients with GOLD 4 disease (51.6%) was significantly higher than in all other GOLD classes. The overall mean ages at death were 80.5 years for men and 86.4 years for women, respectively, which were very close to the life expectancy of 81.3 years for men and 87.3 years for women in the general population of HK. There was an inverse relationship of GOLD class with the age at death. Patients with GOLD 4 disease had the lowest mean age at death of 75.4 years for men and 81.0 years for women. The difference was statistically significant for men but not for women, probably because of the smaller number of female patients. For patients without lung function coding, the mean age at death (M: 81.1 years, F: 86.8 years) was greater than that of those with lung function coding (M: 78.2 years, F: 83.0 years; *p*\<0.0001).

In total, 1,585 of 9,776 (16.2%) patients died in the HA hospitals in 2012, while 8,191 of 9,776 patients (83.8%) survived after their last discharge from the HA hospitals in 2012. Using the last discharge date from the HA hospitals in 2012 as the index date, the top 5 causes of death of these patients in the HA hospitals in 2012, at 1 year (1--365 days) after discharge and at 2 years (366--730 days) after discharge, are listed in [Table 6](#t6-copd-13-1913){ref-type="table"}. The top 5 causes of death in the HA hospitals were COPD, pneumonia, lung cancer, respiratory failure, and other malignancies with no significant variation observed over the 2-year period. The 1-year mortality rate after discharge in 2012 was 1,175/8,191 (14.3%); 1,245 patients died in the second year. The 2-year mortality rate was 2,420/8,191 (29.5%).

Discussion
==========

The use of electronic medical record databases makes it possible to study large patient cohorts. Studies had been carried out with the UK Clinical Practice Research Datalink GOLD to study exacerbations in COPD patients in primary care.[@b13-copd-13-1913] We have collected hospital admission data of a large COPD cohort using a computerized system (CDARS).[@b10-copd-13-1913],[@b11-copd-13-1913] To the best of our knowledge, this is the first study of this kind for COPD patients in HK. We have chosen to investigate the common parameters including demographic data, use of hospital services such as hospital stays, A&E attendance, use of NIV, and medication prescription in patients with different GOLD classes. These parameters provide important statistical figures for the estimation of disease burden and consumption of health care resources. In future, it is possible to extend the study to other parameters and make correlations between different subgroups. As most of the analytical work with CDARS can be performed with statistical manipulation, but without additional data entry, it is possible to repeat the study within a short period at low cost and have near real-time monitoring of the parameters of interest. It is also possible to track information and outcome of subgroups over time.

HK is a densely populated city with \>7.3 million citizens. There are more women than men in HK with a male-to-female ratio of around 1:1.18. The expectation of life for men and women as in 2016 was 81.3 and 87.3 years, respectively (Census and Statistics Department, the Government of HK Special Administrative Region \[HKSAR\]).[@b14-copd-13-1913] About 95% of the population depended on the HA for hospital service, which is heavily subsidized by the government. Free ambulance service is provided to patients in need in any area of the territory. The most significant "bottleneck" to hospital admission appears to be the availability of hospital beds, and only patients with more severe diseases could be admitted.

The present study included all except one regional acute general medical department and all except one chest hospital in HK in 2012--2014. We believed that the information obtained from this study would be a representative of the total picture of COPD admissions in HK. This study will help to provide information on the burden of COPD on the public hospital health care system, the case mix, and severity of COPD in HK and provide reference for resource and manpower allocation in the future. The information would probably also provide useful reference for other countries in Asia.

This study captured the data of 19,795 episodes of admissions with \>9,000 patients admitted to public hospitals in HK with the principal diagnosis of COPD in 2012. We found that the majority of COPD patients were elderly men. The predominance of male patients may limit the generalization of our findings to female patients. Many patients were not using the appropriate medications as recommended by the GOLD guidelines.[@b12-copd-13-1913] In total, 61% of our patients had at least one of the comorbid illnesses (hypertension, ischemic heart disease, diabetes mellitus, old TB, bronchiectasis, congestive heart failure, and asthma).

Only about 20% of our patients had lung function coding entered in 2012. The lung function could have been performed in 2012 or earlier. The coding would also include the severity of COPD according to the ranges of the GOLD[@b12-copd-13-1913] stages once it was entered. The coding of lung function is not mandatory for the CMS in HA. The attending physician could choose not to code the lung function even if it had been performed. We expected the percentage of patients with lung function ever performed to be much \>20%. Our previous pilot study with case record review[@b10-copd-13-1913] showed that 64% of COPD patients admitted to hospital had at least one spirometry that was ever performed. It appeared from the present study ([Table 2](#t2-copd-13-1913){ref-type="table"}) that patients with more A&E attendance, hospitalizations, and clinic follow-ups were more likely to have the spirometry coding entered by the attending physicians. It also appeared that the group with spirometry coding had more severe COPD and/or exacerbation as their hospital stay was longer (17.9 vs 11.0 days, *p*\<0.001), and many more of them required NIV support (39.8% vs 19.3%, *p*\<0.001) compared with patients without lung function coding. The group without lung function coding appeared to have less severe disease/exacerbation, but their mortality rate was paradoxically higher than that of the group with lung function coding (46.1% vs 42.1%, *p*\<0.002). The mean ages at death of the group without lung function coding were 81.1 and 86.8 years for men and women, respectively, which were very close to the life expectancy for the general population (81.3 and 87.3 years, respectively). The higher mortality in this group could perhaps be explained by a natural course of disease toward the end of life.

A recent study in the USA found that about 70% of the participants of the surveys had undiagnosed COPD as revealed with spirometry. For those with airflow obstruction, their risk of death was increased compared with subjects without airflow obstruction.[@b15-copd-13-1913] Another recent study found that airflow obstruction at the age of 55 years was an important risk factor for future COPD hospitalizations.[@b16-copd-13-1913] Poor lung function has been associated with an increased risk of exacerbations. Previous studies had shown that exacerbations became more frequent and more severe as the severity of COPD increased.[@b13-copd-13-1913],[@b17-copd-13-1913],[@b18-copd-13-1913] We have the same observation in this study in which those with poorer lung function had more admissions for COPD, more frequent need for NIV support, longer length of hospital stay as well as higher mortality.

Our data did not allow us to group the subjects according to the GOLD guideline^12^-recommended A, B, C, and D groups as we did not have the symptoms scores coding in the CMS. As all these subjects had at least one admission for COPD in 2012, they should all belong to group C or D according to the GOLD guideline[@b12-copd-13-1913] after their first admission to hospital in 2012. For subjects in GOLD group C or D, it is recommended that subjects should be on at least ICS + LABA and/or LAMA. However, we found that only 24% of our patients were given prescriptions according to this guideline after discharge from hospital. Recent published data from HK also showed that there was suboptimal adherence to GOLD guideline, and overprescription of ICS was identified.[@b19-copd-13-1913] Optimization of the drug therapy would help to reduce the risk of developing acute exacerbation of COPD (AECOPD). Combination of ICS and LABA could lead to around a quarter fewer AECOPD than were seen with placebo.[@b20-copd-13-1913] Tiotropium can also reduce the odds of COPD exacerbations (OR =0.74, 95% CI =0.66--0.83) and related hospitalizations (OR =0.64; 95% CI =0.51--0.82) compared with placebo or ipratropium.[@b21-copd-13-1913]

A recent study[@b22-copd-13-1913] has shown that with the omission of spirometry in 2017 GOLD ABCD classification,[@b23-copd-13-1913] the revised system shifted many patients from C and D to A and B, possibly leading to reduced intensity of therapies. On the other hand, treatment with acute NIV for COPD admissions was more likely guided by the arterial blood gases. Our study showed that patients with GOLD 3 and 4 diseases were more likely to be treated with NIV than patients with GOLD 1 and 2 diseases. An earlier longitudinal study had also demonstrated that FEV~1~ was one of the factors associated with mortality risk in COPD.[@b24-copd-13-1913] Patients with compensated and decompensated respiratory acidosis had poorer lung function and higher risk of death/life-threatening events compared with patients with normocapnia.[@b25-copd-13-1913] Exacerbations were also more common in patients with poorer lung function.[@b13-copd-13-1913],[@b17-copd-13-1913],[@b18-copd-13-1913] Further studies are warranted to find out whether spirometry may have prognostic value in predicting the frequent exacerbators, development of type 2 respiratory failure, need of NIV, and mortality in patients with COPD.

Among the comorbidities, hypertension (40% of all subjects) was the commonest comorbidity followed by diabetes mellitus (15%) and cardiac diseases (congestive heart failure: 13.9%; and ischemic heart disease: 11.3%). A previous study[@b26-copd-13-1913] found that hypertension, hyperlipidemia, and coronary artery diseases are the 3 commonest comorbidities, and this was similar to the findings in the present study. Other comorbidities including anxiety/depression, heart failure, pulmonary hypertension, and metabolic syndrome had been reported.[@b27-copd-13-1913] Clinicians should screen their COPD patients for the presence of comorbidities for which specific treatments are available and are associated with better COPD outcomes.[@b28-copd-13-1913] Vascular comorbidities in COPD may have a direct impact on patient survival.[@b29-copd-13-1913] In total, 9.0% and 7.5% of our subjects had chronic effects of TB and bronchiectasis, respectively. Self-reported TB was a risk factor for COPD in nonsmokers.[@b30-copd-13-1913] A history of TB should be considered as a potentially important cause of obstructive lung disease, particularly where TB is common.[@b31-copd-13-1913] HK has quite a high prevalence of TB (in 2015, total notifications of 4,498 cases with a notification rate of 61.63 per 100,000 population).[@b32-copd-13-1913]

The all-cause mortality rate in the HA hospitals was 16.2% in 2012. This was much higher than the yearly mortality rate (4%--5%) in a study from the USA for AECOPD.[@b33-copd-13-1913] In this study, about 3% and 6% of the subjects required NIV and IMV support, respectively. In total, 23.3% of our COPD patients required NIV support, but a much lower rate of IMV (1.4%). A previous study found that the assignment of do-not-resuscitate status was the most significant independent predictor of avoiding intubation (OR =0.11, 95% CI =0.03--0.37).[@b34-copd-13-1913] As we have not collected the data of do-not-resuscitate status, we were not sure if this could have contributed to the lower rate of IMV in our subjects.

On 31 December 2014 (after \>2 years of discharge from hospital for the first episode of COPD in 2012), 4,427 (45.3%) of the original cohort of 9,776 patients had died (3,867 \[39.6%\] within the HA hospitals; [Table 5](#t5-copd-13-1913){ref-type="table"}). The high mortality in our group of patients was comparable to the previously reported high mortality of 22%--43% after 1 year and 36%--48% after 2 years following hospital admission reported from the USA, the Netherlands, and Spain.[@b35-copd-13-1913]--[@b38-copd-13-1913] The high cumulative mortality in our group of patients could perhaps be explained by their relatively older age (mean age at death of 80 and 86 years for men and women, respectively) and the severity of their illness as reflected by the high percentage of patients requiring NIV. The availability of hospital beds precludes the admission of patients with milder disease, and only patients with more severe disease could be admitted. The lower denominator would increase the mortality rate in areas where bed availability is a problem.

A study conducted in Spain showed that the mortality rate was 35.6% at 2 years following hospital discharge for COPD; 50% of patients died from respiratory diseases and 19% from cardiovascular diseases.[@b37-copd-13-1913] An earlier single-center, prospective study in HK (243 COPD subjects) showed a mortality rate of 25% over 3 years.[@b39-copd-13-1913] The common causes of death were COPD (24.9%), pneumonia (6.6%), and lung cancer (13.1%). In our present study, the 2-year mortality rate after hospital discharge was 29.5% ([Table 6](#t6-copd-13-1913){ref-type="table"}). The top causes of death were similar -- pneumonia, COPD, and lung cancer, but the percentages were somewhat different (32.2%, 21.8%, and 4.4% respectively), probably related to case selection in the earlier prospective study. Cardiovascular comorbidities were common in COPD patients in HK[@b10-copd-13-1913],[@b39-copd-13-1913] ([Table 4](#t4-copd-13-1913){ref-type="table"}; [Figure 1](#f1-copd-13-1913){ref-type="fig"} \[in the present study\]), but the incidence of cardiovascular deaths was disproportionately low in the present study (5.5%; [Table 5](#t5-copd-13-1913){ref-type="table"}) as well as in earlier studies in HK.[@b10-copd-13-1913],[@b39-copd-13-1913] It is possible that the cardiovascular symptoms were masked by the overwhelming respiratory events in our critically ill COPD patients. A significant proportion of the subjects might have died of cardiovascular or cerebrovascular diseases outside hospital.

Limitations
===========

The potential limitations of this study were the following: some parameters requiring physician coding may be inaccurate and/or incomplete. Coding for COPD remains a physician-led diagnosis in HK, and unlike the UK system, lung function coding is not mandatory. Only about 20% of the subjects had coding for lung function. For the remaining patients, lung function might or might not be performed. The timing of lung function was also not available in the earlier version of the CMS. This information was recently incorporated in the latest version of the CMS, but manual capture of data is still required. These problems may be solved in future with automatic uploading of the spirometric data to the CMS. The Medical Research Council dyspnea grade and exacerbation rate (apart from the severe exacerbations resulting in hospital admissions) were not included in the present format of the CMS, and a low coding rate is expected even if they are included. Exploration of clinical or biochemical parameters (eg, PaO~2~ and pCO~2~) that do not require manual coding will assist in the development of computerized data collection and analysis for COPD in the future.

Conclusion
==========

It is possible to collect and analyze data of a large COPD cohort using a computerized system. COPD is a disease with high morbidity and mortality. Most subjects were elders with recurrent hospital admissions, and NIV support was required in 23% of subjects. Many of them were not on optimal medical therapy for COPD. Pneumonia and COPD were common causes of mortality. Improved care of COPD patients by optimizing their pharmacological treatment and management of their comorbidities may improve outcomes. Palliative care could be planned in advance for patients with poor prognostic factors.

Supplementary material
======================

List of hospitals included in the study
---------------------------------------

### General hospitals

Alice Ho Miu Ling Nethersole Hospital, Caritas Medical Centre, Kwong Wah Hospital, North District Hospital, Pamela Youde Nethersole Eastern Hospital, Queen Elizabeth Hospital, Queen Mary Hospital, Prince of Wales Hospital, Princess Margaret Hospital, the Ruttonjee and Tang Shiu Kin Hospital, Tseung Kwan O Hospital, Tuen Mun Hospital, and United Christian Hospital.

### Chest hospitals

Grantham Hospital, Haven of Hope Hospital, and Kowloon Hospital.
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![Prevalence of comorbidities in COPD subjects according to GOLD classification (^\#^*p*=0.001; ^\*^*p*=0.048).\
**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; TB, tuberculosis.](copd-13-1913Fig1){#f1-copd-13-1913}

###### 

Demographic characteristics of the subjects (obtained from the first admission within the year 2012) with or without lung function coding

  Characteristics                                   All subjects                               GOLD 1                                       GOLD 2                                     GOLD 3                                     GOLD 4                                      *p*-value                                                                                                  GOLD 1--4                                  No lung function coding                    *p*-value     GOLD 1--2                                  GOLD 3--4                                  *p*-value
  ------------------------------------------------- ------------------------------------------ -------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------------ ------------- ------------------------------------------ ------------------------------------------ -------------
  Number                                            9,776                                      85                                           488                                        808                                        537                                                                                                                                                    1,918                                      7,858                                                    573                                        1,345                                      
  Male (%)                                          8,079 (82.6)                               74 (87.1)                                    421 (86.3)                                 743 (92.0)                                 483 (89.9)                                  **0.044**                                                                                                  1,721 (89.7)                               6,358 (80.9)                               \<**0.001**   495 (86.4)                                 1,226 (91.2)                               **0.002**
  Age (years); mean (SD)                            78.0 (9.4); M: 77.0 (9.2); F: 83.1 (8.4)   77.7 (10.8); M: 76.5 (10.8); F: 85.5 (6.6)   77.8 (8.2); M: 77.3 (8.0); F: 80.7 (8.9)   76.0 (8.3); M: 75.5 (8.3); F: 80.8 (6.4)   73.4 (8.6); M: 72.9 (8.3); F: 77.4 (10.3)   GOLD 1 vs 4, ***p***=**0.004**; GOLD 2 vs 3, ***p***=**0.001**; GOLD 2 vs 4 & 3 vs 4, ***p***\<**0.001**   75.8 (8.6); M: 75.3 (8.5); F: 80.1 (8.7)   78.6 (9.4); M: 77.4 (9.3); F: 83.5 (8.3)   \<**0.001**   77.8 (8.7); M: 77.2 (8.5); F: 81.4 (8.8)   74.9 (8.5); M: 74.5 (8.4); F: 79.2 (8.6)   \<**0.001**
  Number of hospital admission in 2012; mean (SD)   2.03 (2.00)                                2.07 (3.03)                                  2.37 (2.34)                                2.59 (2.50)                                3.28 (2.97)                                 GOLD 1 vs 4, ***p***=**0.005**; GOLD 2 vs 4 & 3 vs 4, ***p***\<**0.001**                                   2.70 (2.65)                                1.86 (1.77)                                \<**0.001**   2.32 (2.46)                                2.87 (2.72)                                \<**0.001**

**Notes:** GOLD 1--2 = GOLD 1 + GOLD 2; GOLD 3--4 = GOLD 3 + GOLD 4; GOLD 1--4 = GOLD 1 + GOLD 2 +GOLD 3 + GOLD 4. Bold figures indicate statistically significant (*p*\<0.05).

**Abbreviations:** F, female; GOLD, Global Initiative for Chronic Obstructive Lung Disease; M, male.

###### 

Use of health care resources of subjects according to the GOLD classification

                                                         All subjects   GOLD 1        GOLD 2         GOLD 3         GOLD 4         *p*-value                                                                                 GOLD 1--4     No lung function coding   *p*-value     GOLD 1--2     GOLD 3--4     *p*-value
  ------------------------------------------------------ -------------- ------------- -------------- -------------- -------------- ----------------------------------------------------------------------------------------- ------------- ------------------------- ------------- ------------- ------------- -------------
  Number                                                 9,776          85            488            808            537                                                                                                      1,918         7,858                                   573           1,345         
  Number of A&E attendance/headcount; mean (SD)          3.8 (4.9)      5.8 (20.0)    4.1 (4.0)      4.2 (5.5)      4.4 (4.2)      NS                                                                                        4.3 (6.3)     3.6 (4.4)                 \<**0.001**   4.3 (8.5)     4.3 (5.0)     0.944
  Number of SOPC attendance/headcount; mean (SD)         2.5 (2.5)      2.4 (2.9)     2.8 (2.4)      3.1 (2.5)      3.2 (2.5)      GOLD 2 vs 4, ***p***=**0.031**                                                            3.0 (2.5)     2.3 (2.5)                 \<**0.001**   2.7 (2.5)     3.1 (2.5)     **0.002**
  Number of hospital admissions/headcount; mean (SD)     2.0 (2.0)      2.1 (3.0)     2.4 (2.3)      2.6 (2.5)      3.3 (3.0)      GOLD 1 vs 4, ***p***=**0.005**; GOLD 2 vs 4 & 3 vs 4, ***p***\<**0.001**                  2.7 (2.7)     1.9 (1.8)                 \<**0.001**   2.3 (2.5)     2.9 (2.7)     \<**0.001**
  NIV support during acute admission; number (%)         2,278 (23.3)   17 (20)       146 (29.9)     291 (36.0)     309 (57.5)     \<**0.001**                                                                               763 (39.8%)   1,515 (19.3%)             \<**0.001**   163 (28.4%)   600 (44.6%)   \<**0.001**
  IMV support during acute admission number (%)          134 (1.4%)     2 (2.4)       7 (1.4)        13 (1.6)       15 (2.8)       0.211                                                                                     37 (1.9%)     108 (1.4%)                0.072         9 (1.6%)      28 (2.1%)     0.456
  Length of hospital stay/headcount in days; mean (SD)   12.3 (18.5)    9.72 (14.0)   13.74 (20.5)   17.46 (24.2)   23.49 (28.5)   GOLD 1 vs 3, 1 vs 4, 2 vs 4, 3 vs 4, ***p***\<**0.001**; GOLD 2 vs 3, ***p***=**0.017**   17.9 (24.6)   11.00 (16.5)              \<**0.001**   13.1 (19.7)   19.9 (26.2)   \<**0.001**
  COPD deaths in 2012; number (%)                        503 (5.1%)     1 (1.2)       17 (3.5)       31 (3.8)       51 (9.5)       \<**0.001**                                                                               100 (5.2)     403 (5.1)                 0.88          18 (3.1)      82 (6.1)      **0.008**

**Notes:** GOLD 1--2 = GOLD 1 + GOLD 2; GOLD 3--4 = GOLD 3 + GOLD 4; GOLD 1--4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant (*p*\<0.05).

**Abbreviations:** A&E, accident and emergency departments; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IMV, invasive mechanical ventilation; NIV, noninvasive mechanical ventilation; NS, not significant; SOPC, specialist outpatient clinics.

###### 

Medications use of subjects according to the GOLD classification

                              All subjects (n=9,776)   GOLD 1 (n=85)   GOLD 2 (n=488)   GOLD 3 (n=808)   GOLD 4 (n=537)   *p*-value     GOLD 1--4 (n=1,918)   No lung function coding (n=7,858)   *p*-value     GOLD 1--2 (n=573)   GOLD 3--4 (n=1,345)   *p*-value
  --------------------------- ------------------------ --------------- ---------------- ---------------- ---------------- ------------- --------------------- ----------------------------------- ------------- ------------------- --------------------- -------------
  Not on LABA/LAMA/ICS        1,483 (15.2%)            16 (18.8%)      35 (7.2%)        20 (2.5%)        8 (1.5%)         \<**0.001**   79 (4.1%)             1,404 (17.9%)                       \<**0.001**   51 (8.9%)           28 (2.1%)             \<**0.001**
  LABA alone                  965 (9.9%)               8 (9.4%)        73 (15.0%)       102 (12.6%)      39 (7.3%)        **0.002**     222 (11.6%)           743 (9.5%)                          **0.005**     81 (14.1%)          141 (10.5%)           **0.022**
  LAMA alone                  93 (1.0%)                1 (1.2%)        5 (1.0%)         10 (1.2%)        10 (1.9%)        0.276         26 (1.4%)             67 (0.9%)                           **0.042**     6 (1.0%)            20 (1.5%)             0.446
  ICS alone                   3,285 (33.6%)            32 (37.6%)      130 (26.6%)      123 (15.2%)      27 (5.0%)        \<**0.001**   312 (16.3%)           2,973 (37.8%)                       \<**0.001**   162 (28.3%)         150 (11.2%)           \<**0.001**
  LABA + LAMA                 1,605 (16.4%)            8 (9.4%)        110 (22.5%)      260 (32.2%)      243 (45.3%)      \<**0.001**   621 (32.4%)           984 (12.5%)                         \<**0.001**   118 (20.6%)         503 (37.4%)           \<**0.001**
  ICS + LABA (without LAMA)   988 (10.1%)              11 (12.9%)      57 (11.7%)       71 (8.8%)        34 (6.3%)        **0.001**     173 (9.0%)            815 (10.4%)                         0.078         68 (11.9%)          105 (7.8%)            **0.004**
  ICS + LAMA (without LABA)   329 (3.4%)               3 (3.5%)        28 (5.7%)        60 (7.4%)        27 (5.0%)        0.96          118 (6.2%)            211 (2.7%)                          \<**0.001**   31 (5.4%)           87 (6.5%)             0.377
  ICS + LABA + LAMA           1,028 (10.5%)            6 (7.1%)        50 (10.2%)       162 (20.0%)      149 (27.7%)      \<**0.001**   367 (19.1%)           661 (8.4%)                          \<**0.001**   56 (9.8%)           311 (23.1%)           \<**0.001**

**Notes:** GOLD 1--2 = GOLD 1 + GOLD 2; GOLD 3--4 = GOLD 3 + GOLD 4; GOLD 1--4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant (*p*\<0.05).

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonists; LAMA, long-acting anti-muscarinic agent.

###### 

Comorbidities of subjects according to the GOLD classification

  Comorbidities              All subjects (n=9,776)   GOLD 1--4 (n=1,918)   No lung function coding (n=7,858)   *p*-value     GOLD 1--2 (n=573)   GOLD 3--4 (n=1,345)   *p*-value
  -------------------------- ------------------------ --------------------- ----------------------------------- ------------- ------------------- --------------------- -----------
  Hypertension               3,932 (40.2%)            709 (37.0%)           3,223 (41.0%)                       **0.001**     238 (41.5%)         471 (35.0%)           **0.007**
  Ischemic heart disease     1,106 (11.3%)            240 (12.5%)           866 (11.0%)                         0.064         74 (12.9%)          166 (12.3%)           0.729
  Diabetes mellitus          1,469 (15.0%)            263 (13.7%)           1,206 (15.3%)                       0.72          95 (16.6%)          168 (12.5%)           **0.017**
  Chronic effect of TB       877 (9.0%)               239 (12.5%)           638 (8.1%)                          \<**0.001**   64 (11.2%)          175 (13.0%)           0.264
  Bronchiectasis             738 (7.5%)               186 (9.7%)            552 (7.0%)                          \<**0.001**   46 (8.0%)           140 (10.4%)           0.107
  Congestive heart failure   1,359 (13.9%)            200 (10.4%)           1,159 (14.7%)                       \<**0.001**   64 (11.2%)          136 (10.1%)           0.488
  Asthma                     342 (3.5%)               77 (4.0%)             265 (3.4%)                          0.17          25 (4.4%)           52 (3.9%)             0.612

**Notes:** GOLD 1--2 = GOLD 1 + GOLD 2; GOLD 3--4 = GOLD 3 + GOLD 4; GOLD 1--4 = GOLD 1 + GOLD 2 + GOLD 3 + GOLD 4. Bold figures indicate statistically significant (*p*\<0.05).

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; TB, tuberculosis.

###### 

Cumulative mortality as on 31 December 2014 in the different groups of patients

  Principal diagnosis on last discharge with mortality                                                                                 All subjects (n=9,776)                                   GOLD 1 (n=85)                                       GOLD 2 (n=488)                                        GOLD 3 (n=808)                                        GOLD 4 (n=537)                                        No lung function coding (n=7,858)
  ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------
  Pneumonia                                                                                                                            1,250 (32.3%)                                            8 (34.8%)                                           45 (28.1%)                                            76 (27.0%)                                            47 (19.3%)                                            1,074 (34.0%)
  COPD                                                                                                                                 1,164 (30.1%)                                            3 (13%)                                             40 (25.0%)                                            92 (32.7%)                                            111 (45.7%)                                           918 (29.1%)
  Lung cancer                                                                                                                          243 (6.3%)                                               3 (13%)                                             18 (11.3%)                                            24 (8.5%)                                             8 (3.3%)                                              190 (6.0%)
  Other malignancies                                                                                                                   156 (4.0%)                                               0 (0%)                                              7 (4.4%)                                              6 (2.1%)                                              9 (3.7%)                                              134 (4.2%)
  Respiratory failure                                                                                                                  151 (3.9%)                                               0 (0%)                                              1 (0.6%)                                              20 (7.1%)                                             16 (6.6%)                                             115 (3.6%)
  Ischemic heart disease                                                                                                               104 (2.7%)                                               0 (0%)                                              4 (2.5%)                                              8 (2.8%)                                              4 (1.6%)                                              88 (2.8%)
  Sepsis and other systemic infections                                                                                                 102 (2.6%)                                               1 (4.3%)                                            8 (5.0%)                                              6 (2.1%)                                              4 (1.6%)                                              83 (2.6%)
  Heart failure                                                                                                                        71 (1.8%)                                                1 (4.3%)                                            5 (3.1%)                                              6 (2.1%)                                              4 (1.6%)                                              55 (1.7%)
  Renal failure                                                                                                                        40 (1.0%)                                                0 (0%)                                              1 (0.6%)                                              3 (1.1%)                                              2 (0.8%)                                              34 (1.1%)
  Cerebrovascular accident                                                                                                             37 (1.0%)                                                0 (0%)                                              0 (0%)                                                4 (1.4%)                                              2 (0.8%)                                              31 (1.0%)
  Others                                                                                                                               549 (14.3%)                                              7 (30.4%)                                           31 (19.4%)                                            36 (12.1%)                                            36 (15.0%)                                            439 (13.9%)
  All-cause mortality in HA hospital (%)                                                                                               3,867/9,776 (39.6%)                                      23/85 (27.1%)                                       160/488 (32.8%)                                       281/808 (34.8%)                                       243/537 (45.3%)                                       3,160/7,858 (40.2%)
  Death outside HA hospital (%)                                                                                                        560/9,776 (5.7%)                                         4/85 (4.7%)                                         23/488 (4.7%)                                         40/808 (5.0%)                                         34/537 (6.3%)                                         459/7,858 (5.8%)
  Total mortality -- in and outside HA hospital (%)[\#](#tfn9-copd-13-1913){ref-type="table-fn"}                                       **4,427/9,776 (45.3%)**                                  **27/85 (31.8%)**                                   **183/488 (37.5%)**                                   **321/808 (39.7%)**                                   **277/537 (51.6%)**                                   **3,619/7,858 (46.1%)**
  Age at death, years; mean (SD), M, F[\*](#tfn10-copd-13-1913){ref-type="table-fn"}, \[actual number of M & F patients with death\]   **M -- 80.5 (8.4) \[3,637\]; F -- 86.4 (7.7) \[790\]**   **M -- 83.3 (9.9) \[24\]; F -- 89.0 (7.3) \[3\]**   **M -- 80.9 (7.1) \[157\]; F -- 84.4 (6.7) \[26\]**   **M -- 78.5 (7.5) \[299\]; F -- 83.6 (5.1) \[22\]**   **M -- 75.4 (7.9) \[243\]; F -- 81.0 (8.4) \[34\]**   **M -- 81.1 (8.4) \[2,914\]; F -- 86.8 (7.6) \[705\]**

**Notes:**

GOLD 1--2 vs GOLD 3--4, ***p***=**0.002**; GOLD 1 vs GOLD 4, ***p***=**0.002**; GOLD 2 vs GOLD 4, ***p***\<**0.0001**; GOLD 3 vs GOLD 4, ***p***\<**0.0001**. GOLD 1--4 vs no lung function, 42.1% vs 46.1%, ***p***=**0.002**.

M: GOLD 1 vs GOLD 4, *p*=0.005; GOLD 2 vs GOLD 3, *p*=0.005; GOLD 2 vs GOLD 4, *p*\<0.0001; GOLD 3 vs GOLD 4, *p*\<0.0001; GOLD 1--2 vs GOLD 3--4, *p*\<0.0001; GOLD 1--4 vs no lung function coding, *p*\<0.0001; F: GOLD 1--4, *p*=NS; GOLD 1--4 vs no lung function coding, *p*\<0.0001. Bold figures indicate statistically significant (*p*\<0.05).

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; HA, Hospital Authority; NS, not significant.

###### 

Top 5 causes of in-hospital mortality in 2012 and at 1 year and 2 years of discharge from hospital

  Mortality in and outside HA hospitals                                                                  Death within 2012   1 year after hospital discharge in 2012   2 years after hospital discharge in 2012                                             
  ------------------------------------------------------------------------------------------------------ ------------------- ----------------------------------------- ------------------------------------------ ------------------------- --------------- ------------
  Top 5 causes of mortality in HA hospital (number, % of total mortality, in and outside HA hospitals)   1\. COPD            503 (31.7)                                1\. COPD                                   303 (25.8)                1\. Pneumonia   401 (32.2)
  2\. Pneumonia                                                                                          456 (28.8)          2\. Pneumonia                             282 (24.0)                                 2\. COPD                  271 (21.8)      
  3\. Lung cancer                                                                                        107 (6.8)           3\. Lung cancer                           66 (5.6)                                   3\. Lung cancer           55 (4.4)        
  4\. Respiratory failure                                                                                69 (4.4)            4\. Other malignancies                    37 (3.1)                                   4\. Other malignancies    53 (4.3)        
  5\. Other malignancies                                                                                 48 (3.0)            5\. Respiratory failure                   31 (2.6)                                   5\. Respiratory failure   38 (3.1)        
  Total mortality in HA hospital (number)                                                                1,585               831                                       1,092                                                                                
  Death outside HA hospital (number)                                                                     0                   344                                       153                                                                                  
  Total mortality (in and outside HA hospital) (number)                                                  1,585               1,175                                     1,245                                                                                

**Abbreviation:** HA, Hospital Authority.
